Home | Links | Contact Us | More About Intellectual Property | Bookmark
Search patents:
Home Gene Therapy Mimotopes-and-anti-mimotopes-of-human-platelet-glycoprotein-Ib-IX

 Culturable mitochondrial cells with no nucleus, showing mitochondrial activity
OF THE INVENTION Hereinafter, the present invention will be described in detail. (1) Method of P...


 Antisense oligonucleotides inhibiting human bcl-2 gene expression
The invention provides oligodeoxynucleotides and methods for inhibiting growth of lymphoma or ...


 Process for the synthesis of oligomeric compounds
What is claimed is: 1. A method for the preparation of an oligomeric compound having a moiety of F...


 Process for oligonucleotide synthesis
OF THE PREFERRED EMBODIMENTS The present invention is directed to methods for linking a ...


 Derivatized oligonucleotides having improved uptake and other properties
OF THE INVENTION Antisense therapeutics can be practiced in a variety of organisms ranging from ...


 Process for the synthesis of oligomeric compounds
What is claimed is: 1. A compound having the formula: ##STR38## wherein: X.sub.4 is Z or H; Z is CN,...


 Processes for the synthesis of oligomeric compounds
OF PREFERRED EMBODIMENTS The present invention provides methods for the preparation of oligomeric ...


 Methods of synthesis and use of radiolabelled platinum chemotherapeutic agents
OF THE INVENTION Usually, in the method of synthesis of the radiolabelled platinum ...


 Pharmaceutical composition for diabetic neuropathy
What is claimed is: 1. A method for the prophylaxis of diabetic peripheral neuropathy, which ...


 Rapid single-cycle assay for human immunodeficiency virus type-1 drug resistance
This invention aids in fulfilling this need in the art by providing an in vitro, single cycle, ...


 Mimotopes and anti-mimotopes of human platelet glycoprotein Ib/IX

Details
Inventors: Miller, Jonathan L.; Lyle, Vicki A.;
Assignee: The Research Foundation of State University of New York (Albany, NY)
Primary Examiner: Cunningham; Thomas M.
Assistant Examiner: Lubet; Martha
Attorney, Agent or Firm: Braman & Rogalskyj, LLP

The present invention is directed to an isolated peptide that functionally mimics a binding site for a monoclonal antibody, the monoclonal antibody recognizing an epitope within the human platelet glycoprotein Ib/IX complex. This peptide is called a mimotope. The invention also provides an isolated molecule capable of binding to the peptide, or the mimotope, which molecule can be an antibody, a second peptide, a carbohydrate, a DNA molecule, an RNA molecule, or other naturally or chemically synthesized molecules. This isolated molecule is called an anti-mimotope. Mimotopes mimicking the binding site for monoclonal antibody C-34 and SZ-2, as well as anti-mimotopes to the C-34 mimotopes, are specifically provided.

DETAILED DESCRIPTION The invention provides an isolated peptide that functionally mimics a binding site for a monoclonal antibody, the monoclonal antibody recognizing an epitope within the human glycoprotein Ib/IX complex.
This peptide is called a mimotope.
In one preferred embodiment, the monoclonal antibody is designated C-34, and the peptide includes an amino acid sequence selected from the group consisting of: SEQ ID NO:1: AWNWRYREYV SEQ ID NO:2: KWNWRNKKYV SEQ ID NO:3: LSTWRYFEYV SEQ ID NO:4: YLGWRYSEYV SEQ ID NO:5: TQMWRAREYL SEQ ID NO:6: WRQREYWDPV SEQ ID NO:7: EGSWRYRKGG SEQ ID NO:8: GYHWWRNWEY SEQ ID NO:9: KGFLWRARNW SEQ ID NO:10: MNWKHWRARH SEQ ID NO:11: FKWREWRGKL SEQ ID NO:12: PDRQVRLWVR SEQ ID NO:13: RVLRHWHPRT SEQ ID NO:14: GRRVWMLNHG SEQ ID NO:15: KKGRHHVTRV SEQ ID NO:16: GGVCKCWQCL SEQ ID NO:17: FSHSYGSAIR SEQ ID NO:18: MHGHRRPGLA SEQ ID NO:19: MSKKPHLGLR SEQ ID NO:20: TMWVELYSLK SEQ ID NO:21: FVDPGRAGRG SEQ ID NO:23: FRCCVFSCCLLS SEQ ID NO:24: GFRCLVSLGGCF SEQ ID NO:25: YSLWGLPVGDVV SEQ ID NO:26: LPLLWFNGAGFF SEQ ID NO:27: VWGLFRGLENGS SEQ ID NO:28: SLWRQWRGLFVV SEQ ID NO:29: TLSLFGGRDKGF SEQ ID NO:30: IGPAVSCLFRVC SEQ ID NO:31: MSLFPLSFCRLI SEQ ID NO:32: ALFSSVWGDVTL SEQ ID NO:33: GWFGPFWVRGSG SEQ ID NO:34: FWVSVGGVEGVV SEQ ID NO:35: LGAFGGAGFLWR SEQ ID NO:36: CRGIVFLFVGWL SEQ ID NO:37: FWLVKGAGAWRF SEQ ID NO:39: QVRLWARAGAGQ SEQ ID NO:40: GLAVTFGSVLEG SEQ ID NO:41: VRWMCVIRLGVR SEQ ID NO:42: RLWGPGVSRPVL SEQ ID NO:43: CGSSLFRGPRCP SEQ ID NO:44: LGISSLSFLQLR SEQ ID NO:45: TWGWDGVSYLFL SEQ ID NO:46: TRSLFDDFVSLR SEQ ID NO:47: CYASLFRSRLCA SEQ ID NO:48: DGSVRVVWVRLL SEQ ID NO:49: LSGFPVALVRFA SEQ ID NO:50: LGGGLLVGSVFP SEQ ID NO:51: VWARGVFRDRFF SEQ ID NO:52: TGLLAGPVWRWT SEQ ID NO:53: WLGGIFSCLVCG SEQ ID NO:54: WFLRDVGCGSCL SEQ ID NO:55: SRCGVFTWCSRS SEQ ID NO:56: RCLVGYRCWGGV SEQ ID NO:57: GFRCLVMGGGCA SEQ ID NO:58: CGFDLVCARLFG SEQ ID NO:59: DSGVRWFFGFLG SEQ ID NO:60: ILDGCFFLGRCP SEQ ID NO:61: CVRWLVSAGCSG SEQ ID NO:62: CVGCWLVCDVLL SEQ ID NO:63: CLFVFAAGFACG SEQ ID NO:64: SCALFGSCFGIS SEQ ID NO:65: CWGGVGVCGLLV SEQ ID NO:66: KRAWWKQKWV SEQ ID NO:67: CVGGVASRCGVL SEQ ID NO:68: SGAVLAGPFGVW SEQ ID NO:69: CRAFDRVGVCVW SEQ ID NO:70: RCLVGYVVWGGVW SEQ ID NO:71: VCLVYRSVDCWA SEQ ID NO:72: WRVFVFTCVVWA SEQ ID NO:73: LWREWRGLFAVL SEQ ID NO:74: SGAVLAGPLWRL SEQ ID NO:75: FVVRGGTFLFVR SEQ ID NO:77: TGLLAGPVWRWT SEQ ID NO:78: DSGVRWFFGFLG SEQ ID NO:79: CAWHRLSFCGLV SEQ ID NO:80: CFGSALVLAVLA and SEQ ID NO:81: WFWDMSGEWGGL



Related patents
  Adjuvant and vaccine compositions containing monophosphoryl lipid A
What is claimed: 1. A lyophilized composition comprising 0.2% up to 5% by weight 3-O-desacyl-4'-monophosphoryl lipid A, at least 70% by weight of sugar and 0% to about 30...
  Methods for preparation of vaccines against cancer
The present invention relates to methods for producing increased amounts of immunogenic material which can be used for prevention and treatment of cancer. The ...
  Human genes and gene expression products V
OF THE INVENTION The invention relates to polynucleotides comprising the disclosed nucleotide sequences, to full length cDNA, mRNA genomic sequences, and genes ...
  Haptotactic peprides
The invention claimed is: 1. An isolated haptotactic peptide of 20 amino acids consisting of the amino acid sequence as set forth in SEQ ID NO:1, characterized in that ...
  Hepatitis C virus inhibitors
OF THE INVENTION Stereochemical definitions and conventions used herein generally follow McGraw-Hill Dictionary of Chemical Terms, S. P. Parker, Ed., McGraw-Hill Book C...
  Expression of recombinant glyoprotein B from herpes simplex virus
The nucleotide sequence and the amino acid sequence derived therefrom are provided for Herpes Simplex Virus ("HSV") glycoprotein B ("gB") for use in expression of the ...
  Enhancing agent for nerve growth factor production comprising a compound having a coumarin backbone or a compound having a 2-dimethyl chroman backbone
The invention claimed is: 1. A therapeutic agent or prophylactic agent for a disease requiring enhancement of nerve growth factor production, wherein the therapeutic ...
  In vitro packaging of adeno-associated virus DNA
It is an object of the present invention to provide a method for packaging a DNA substrate in an in vitro reaction to produce adeno-associated virus (AAV) particles ...
  Recombinant viral vector system
The present invention relates to the in vitro synthesis of a novel 165 basepair fragment of DNA which contains AAV ITR sequences and which can be synthesized in vitro ...
  Modified adeno-associated virus vector capable of expression from a novel promoter
This invention provides an adeno-associated viral vector comprising the inverted terminal repeat sequences of adeno-associated virus and a nucleic acid, wherein the ...

0.014

Archive: All patents - Links

Copyright (c)2006 Eipa-patents.org - All rights reserved